Bibliography
The links in this bibliography were up-to-date as of publication.
An asterisk (*) denotes an item that was particularly useful in the preparation of this issue of Population Reports.
A cross (†) denotes an item that was particularly useful in the preparation of this issue of INFO Reports.
1. ADDA, C. First among equals! Cecilia Adda discusses her experience as CHO. Navrongo Community Health and Family Planning Project Newsletter 4(22). 2004. (Available: http://www.ghana-chps.org/pdfs/ww/WHATWORKS.CHAP6.pdf)
2. AGUILAR, Z., DUARTE, T., BRATT, J., BRAMBILA, C., and FOREIT, J. Willingness to pay for reproductive health services among APROFAM clients. Washington, D.C., Population Council, Frontiers in Reproductive Health, Dec. 2001. 21 p. (Available: http://pdf.usaid.gov/pdf_docs/PNACN826.pdf)
3. AKBAR, J., CHAKRABORTY, J., JAHAN, N., PHILLIPS, J.F., and SATTERWAITE, A.P. Dynamics of depot medroxy progesterone acetate (DMPA) use effectiveness in the Matlab Family Planning Health Services Project. Presented at the 7th Annual Contributors Conference of Bangladesh Fertility Research Program, Dhaka, Dec. 8–9, 1982.
4. APELO, R.A., DE LA CRUZ, J.R., and CANCIO-LOPEZ, F. Acceptability of injectable contraception in the Philippines. IPPF Medical Bulletin 8(2): 1–2. Apr. 1974.
5. ARENDS-KUENNING, M. Reconsidering the doorstep-delivery system in the Bangladesh Family Planning Program. Studies in Family Planning 33(1): 87–102. Mar. 2002.
6. ARENDS-KUENNING, M. and KESSY, F.L. The impact of demand factors, quality of care and access to facilities on contraceptive use in Tanzania. Journal of Biosocial Science: 1–26. Dec. 19, 2005.
*†7. ARIAS, R.D., JAIN, J.K., BRUCKER, C., ROSS, D., and RAY, A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception 74(3): 234–238. Sep. 2006.
8. ARIWONGSE, B.C. An overview of the FPNP injectable programme. Presented at the Recent Advances in Contraceptive Technology Conference, Chiang Mai, Thailand, Oct. 14–20, 1987.
9. ARMAND, F. The sustainability challenge: Identifying appropriate financing models for social marketing programs. Washington, D.C., Commercial Market Strategies Project, Oct. 2003. (Occasional Paper Series) 42 p.
†10. BAETEN, J.M., NYANGE, P.M., RICHARDSON, B.A., LAVREYS, L., CHOHAN, B., MARTIN, H.L., JR., MANDALIYA, K., NDINYA-ACHOLA, J.O., BWAYO, J.J., and KREISS, J.K. Hormonal contraception and risk of sexually transmitted disease acquisition: Results from a prospective study. American Journal of Obstetrics and Gynecology 185(2): 380–385. Aug. 2001.
*11. BAHAMONDES, L., MARCHI, N.M., NAKAGAVA, H.M., DE MELO, M.L., CRISTOFOLETTI MDE, L., PELLINI, E., SCOZZAFAVE, R.H., and PETTA, C. Self-administration with UniJect of the once-a-month injectable contraceptive Cyclofem. Contraception 56(5): 301–304. Nov. 1997.
12. BAHAMONDES, L., MONTEIRO-DANTAS, C., ESPEJO-ARCE, X., DOS SANTOS FERNANDES, A.M., LUI-FILHO, J.F., PERROTTI, M., and PETTA, C.A. A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants. Human Reproduction 21(2): 466–470. Feb. 2006.
13. BASSOL, S., CRAVIOTO, M.C., DURAND, M., BAILON, R., CARRANZA, S., FUGAROLAS, J., GAONA, R., PARADA, L.M., CELIS, C., and SANTOYO, S. Mesigyna once-a-month combined injectable contraceptive: Experience in Latin America. Contraception 61(5): 309–316. May 2000.
14. BATTERSBY, A., FEILDEN, R., and NELSON, C. Sterilizable syringes: Excessive risk or cost-effective option? Bulletin of the World Health Organization 77(10): 812–819. 1999. (Available: http://whqlibdoc.who.int/bulletin/1999/Vol77-No10/bulletin_1999_77(10)_812-819.pdf)
†15. BEKSINSKA, M.E., SMIT, J.A., KLEINSCHMIDT, I., FARLEY, T.M., and MBATHA, F. Bone mineral density in women aged 40–49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception. Contraception 71(3): 170–175. Mar. 2005.
†16. BELSEY, E.M. The association between vaginal bleeding patterns and reasons for discontinuation of contraceptive use. Contraception 38(2): 207–225. Aug. 1988.
†17. BELSEY, E.M., MACHIN, D., and D'ARCANGUES, C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 34(3): 253–260. Sep. 1986.
*18. BERG, R., KANESATHASAN, N., and BOLLINGER, L. Getting from awareness to use: Lessons learned from SOMARC III about marketing hormonal contraceptives. Washington, D.C., Futures Group International, Social Marketing for Change (SOMARC), Sep. 1998. (SOMARC III Special Study No. 6) 21 p.
*19. BIDDLECOM, A.E. and FAPOHUNDA, B.M. Covert contraceptive use: Prevalence, motivations, and consequences. New York, Population Council, 1998. (Policy Research Division Working Paper No. 108) 37 p. (Available: http://www.popcouncil.org/pdfs/wp/108.pdf)
*20. BIGRIGG, A., EVANS, M., GBOLADE, B.A., NEWTON, J., POLLARD, L., SZAREWSKI, A., THOMAS, C., and WALLING, M. Depo Provera discussion paper on clinical care, effectiveness and side effects. British Journal of Family Planning 26(1): 52–53. Jan. 2000.
21. BLACKBURN, B. (USAID) [Emergency shipments of DMPA from USAID] Personal communication, Jul. 11, 2006.
22. BONNY, A.E., BRITTO, M.T., HUANG, B., SUCCOP, P., and SLAP, G.B. Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA). Journal of Pediatric and Adolescent Gynecology 17(2): 109–115. Apr. 2004.
†23. BONNY, A.E., ZIEGLER, J., HARVEY, R., DEBANNE, S.M., SECIC, M., and CROMER, B.A. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Archives of Pediatrics & Adolescent Medicine 160(1): 40–45. Jan. 2006.
24. BOSSEMEYER, D. and NECOCHEA, E. Standards-based management and recognition: An innovative approach to improving HIV/AIDS service delivery in limited resource settings. Presented at the XVI International AIDS Conference, Toronto, Aug. 13–18, 2006.
*†25. BOYLE, P., CHILVERS, C., FERRAZ, E., HULKA, B., KING, R., LA VECCHIA, C., PETITTI, D., LUMBIGANON, P., SKEGG, D., and THOMAS, D. Depot-medroxyprogesterone acetate (DMPA) and cancer: Memorandum from a WHO meeting. Bulletin of the World Health Organization 71(6): 669–676. 1993. (Available: http://whqlibdoc.who.int/bulletin/1993/Vol71-No6/bulletin_1993_71(6)_669-676.pdf)
26. BRACKEN, M.B. Oral contraception and congenital malformations in offspring: A review and meta-analysis of the prospective studies. Obstetrics and Gynecology 76(3 Pt 2): 552–557. Sep. 1990.
27. BRUCE, J. Fundamental elements of the quality of care: A simple framework. Studies in Family Planning 21(2): 61–91. Mar.–Apr. 1990
28. BURKHART, M. and SOLÓRZANO, J. Testing a tripartite strategy in San Marcos: Final report. Guatemala City, Ministry of Public Health and Social Assistance and Population Council, 1999.
29. CAMPBELL, B. (United Nations Population Fund) [Quick distribution of injectables in Nepal] Personal communication, Jun. 20, 2006.
†30. CANTO DE CETINA, T.E., CANTO, P., and ORDONEZ LUNA, M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception 63(3): 143–146. Mar. 2001.
*31. CASTLE, S., KONATE, M.K., ULIN, P.R., and MARTIN, S. A qualitative study of clandestine contraceptive use in urban Mali. Studies in Family Planning 30(3): 231–248. Sep. 1999.
32. CHU, J.H., GANGE, S.J., ANASTOS, K., MINKOFF, H., CEJTIN, H., BACON, M., LEVINE, A., and GREENBLATT, R.M. Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. American Journal of Epidemiology 161(9): 881–890. May 1, 2005.
33. COHN, S., WATTS, D., LERTORA, J., PARK, J.G., and YU, S. An open-label, non-randomised study of the effect of depo-medroxyprogesterone acetate on the pharmacokinetics of selected protease inhibitors and non-nucleoside reverse transcriptase inhibitors therapies among HIV-infected women. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, Feb. 22–25, 2005.
*34. COLLUMBIEN, M. and DOUTHWAITE, M. Pills, injections and audiotapes: Reaching couples in Pakistan. Journal of Biosocial Science 35(1): 41–58. Jan. 2003.
35. CONTRACEPTIVE TECHNOLOGY UPDATE. Pilot pharmacy program gives injections a shot. Contraceptive Technology Update 22(7): 77–78. Jul. 2001.
36. CONTRACEPTIVE TECHNOLOGY UPDATE. Project takes a shot at contraceptive access. Contraceptive Technology Update 25(10). Oct. 2004.
37. CROSIGNANI, P.G., LUCIANO, A., RAY, A., and BERGQVIST, A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction 21(1): 248–256. Jan. 2006.
38. CROWN AGENTS. What we do: Health sector. {http://www.crownagents.com/sectors.asp?contentID=12§orID=12&navID=103} Crown Agents, 2006.
39. DALLEL, N., KACEM, M., NABOULI, R.M., and EL MAY, M. [Disposal of insulin syringes by diabetic patients. Report of 100 patients]. La Tunisie médicale 83(7): 390–392. Jul. 2005.
40. DANLI, S., QINGXIANG, S., and GUOWEI, S. A multicentered clinical trial of the long-acting injectable contraceptive Depo Provera in Chinese women. Contraception 62(1): 15–18. Jul. 2000.
41. DARNEY, P.D., JAIN, J.K., and JAKIMIUK, A.J. Zero pregnancies with new low-dose DMPA-SC injection for contraception. Presented at the American Society for Reproductive Medicine 60th Annual Meeting, Oct. 16–20, 2004.
42. DARNEY, P.D., JAIN, J.K., and JAKIMIUK, A.J. Zero pregnancies with new low-dose DMPA-SC injection for contraception [abstract]. Presented at the American Society for Reproductive Medicine 60th Annual Meeting, Oct. 16–20, 2004.
43. DE ABOOD, M., DE CASTILLO, Z., GUERRERO, F., ESPINO, M., and AUSTIN, K.L. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. Contraception 56(5): 313–316. Nov. 1997.
*44. DEBPUUR, C., PHILLIPS, J.F., JACKSON, E.F., NAZZAR, A., NGOM, P., and BINKA, F.N. The impact of the Navrongo Project on contraceptive knowledge and use, reproductive preferences, and fertility. Studies in Family Planning 33(2): 141–164. Jun. 2002.
*45. DELIVER. Contraceptive fact sheets. Arlington, Virginia, John Snow, Inc./DELIVER for the U.S. Agency for International Development, Feb. 2006. 22 p. (Available: http://pdf.usaid.gov/pdf_docs/PNADG030.pdf)
46. DKT INTERNATIONAL. Contraceptive social marketing statistics: 1990–2005. {http://www.dktinternational.org/wws.htm} DKT International, Aug. 2006.
47. DOHLIE, M. Supportive supervision. Chapel Hill, North Carolina, PRIME II, Feb. 2002. (PRIME Pages) (Available: http://www.prime2.org/prime2/pdf/2PI_300.swf)
*†48. DRAPER, B.H., MORRONI, C., HOFFMAN, M., SMIT, J., BEKSINSKA, M., HAPGOOD, J., and VAN DER MERWE, L. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception. Cochrane Database of Systematic Reviews 3: CD005214. Jul. 19, 2006.
49. DUFF, G. Updated prescribing advice on the effect of Depo-Provera contraception on bones. Committee on Safety of Medicines, Medicines and Healthcare Products Regulatory Agencies, Nov. 16, 2004. (Available: http://www.medicalnewstoday.com/medicalnews.php?newsid=16676)
50. EBER, M. (Population Services International) [Social marketing of injectables] Personal communication, Aug. 9, 2006.
51. EGYPT MINISTRY OF INFORMATION STATE INFORMATION SERVICE and JOHNS HOPKINS UNIVERSITY POPULATION COMMUNICATION SERVICES. Dr. Karima Mokhtar: Spots on correct contraceptive use. [Video]. 1996.
52. ENGENDERHEALTH. COPE® handbook: A process for improving quality in health services. New York, EngenderHealth, 2003. (EngenderHealth's Quality Improvement Series) 162 p. (Available: http://www.engenderhealth.org/res/offc/qi/cope/handbook/pdf/cope_handbook-a.pdf)
53. FAMILY PLANNING LOGISTICS MANAGEMENT/JOHN SNOW INC. (JSI). Programs that deliver. Logistics' contributions to better health in developing countries. Arlington, Virginia, Published for the U.S. Agency for International Development (USAID). JSI Family Planning Logistics Management Project, 2000. 117 p.
54. FERNANDEZ, V.H., MONTUFAR, E., OTTOLENGHI, E., and ENGE, K.I. Injectable contraceptive service delivery provided by volunteer community promoters. New York, Population Council, 1997. 29 p.
55. FOLCH-LYON, E., DE LA MACORRA, L., and SCHEARER, S.B. Focus group and survey research on family planning in Mexico. Studies in Family Planning 12(12 Pt 1): 409–432. Dec. 1981.
*56. FOREIT, J.R. and FOREIT, K.G. The reliability and validity of willingness to pay surveys for reproductive health pricing decisions in developing countries. Health Policy 63(1): 37–47. Jan. 2003.
57. FOTHERBY, K., YONG-EN, S., HOWARD, G., ELDER, M.G., and MUGGERIDGE, J. Return of ovulation and fertility in women using norethisterone oenanthate. Contraception 29(5): 447–455. May 1984.
*58. FRANKENBERG, E., SIKOKI, B., and SURIASTINI, W. Contraceptive use in a changing service environment: Evidence from Indonesia during the economic crisis. Studies in Family Planning 34(2): 103–116. Jun. 2003.
59. GALLEN, M., LETTENMAIER, C., and GREEN, C.P. Counseling makes a difference. Population Reports Series J, No. 35. Baltimore, Population Information Program, Center for Communication Programs, Johns Hopkins University, Nov. 1987.
60. GARZA-FLORES, J., MORAKS DEL OLMO, A., FUZIWARA, J.L., FIGUEROA, J.G., ALONSO, A., MONROY, J., PEREZ, M., URBINA-FUENTES, M., GUEVARA, S.J., CEDENO, E., BARRIOS, R., FERMAN, J.J., MEDINA, L.M., VELAZQUEZ, E., and PEREZ-PALACIOS, G. Introduction of Cyclofem once-a-month injectable contraceptive in Mexico. Contraception 58(1): 7–12. Jul. 1998.
61. GEBREGIORGIS, Y. (Save the Children) [Injectable services in Ethiopia] Personal communication, May 8, 2006.
†62. GLASIER, A.F., SMITH, K.B., VAN DER SPUY, Z.M., HO, P.C., and CHENG, L. Amenorrhea associated with contraception: An international study on acceptability. Contraception 67(1): 1–8. Jan. 2003.
63. GOVERNMENT OF INDIA DEPARTMENT OF FAMILY WELFARE. Family welfare programme in India. http://mohfw.nic.in/dofw%20website/family%20welfare%20programme/intro.htm 2006.
64. GRAY, R.H. Reduced risk of pelvic inflammatory disease with injectable contraceptives. Lancet 1(8436): 1046. May 4, 1985.
65. GUPTA, N., O'BRIEN, R., JACOBSEN, L.J., DAVIS, A., and ZUCKERMAN, A. Mood changes in adolescents using depot-medroxyprogesterone acetate for contraception: A prospective study. Journal of Pediatric and Adolescent Gynecology 14(2): 71–76. May 2001.
*66. HAAGA, J.G. and MARU, R.M. The effect of operations research on program changes in Bangladesh. Studies in Family Planning 27(2): 76–87. Mar.—Apr. 1996.
67. HAIBA, N.A., EL-HABASHY, M.A., SAID, S.A., DARWISH, E.A., ABDEL-SAYED, W.S., and NAYEL, S.E. Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters. Contraception 39(6): 619–632. Jun. 1989.
68. HALL, P.E. New once-a-month injectable contraceptives, with particular reference to Cyclofem/Cyclo-Provera. International Journal of Gynaecology and Obstetrics 62 (Suppl. 1): S43–56. Aug. 1998.
69. HARVEY, P.D. The impact of condom prices on sales in social marketing programs. Studies in Family Planning 25(1): 52–58. Jan.–Feb. 1994.
70. HASSAN, E.O., EL-NAHAL, N., and EL-HUSSINIE, M. Once-a-month injectable contraceptives, Cyclofem and Mesigyna, in Egypt. Efficacy, causes of discontinuation, and side effects. Contraception 60(2): 87–92. Aug. 1999.
71. HAURI, A.M., ARMSTRONG, G.L., and HUTIN, Y.J. The global burden of disease attributable to contaminated injections given in health care settings. International Journal of STD & AIDS 15(1): 7–16. Jan. 2004.
72. HINDU. Union government drops controversial injectable contraceptives for women. The Hindu Dec. 12, 2001. (Available: http://www.infochangeindia.org/archives1.jsp?secno=3&monthname=March&year=2002&detail=T)
73. HOWARD, G., BLAIR, M., DAVIS, H., and TREACY, M. The effect of norethisterone oenanthate on the full blood count. British Journal of Family Planning 8(4): 125–129. Jan. 1983.
74. HUANG, J., JIANG, D., WANG, X., LIU, Y., FENNIE, K., BURGESS, J., and WILLIAMS, A.B. Changing knowledge, behavior, and practice related to universal precautions among hospital nurses in China. Journal of Continuing Education in Nursing 33(5): 217–224. Sep.—Oct. 2002.
*75. HUBACHER, D., GOCO, N., GONZALEZ, B., and TAYLOR, D. Factors affecting continuation rates of DMPA. Contraception 60(6): 345–351. Dec. 1999.
*76. HUBACHER, D., HOLTMAN, M., FUENTES, M., PEREZ-PALACIOS, G., and JANOWITZ, B. Increasing efficiency to meet future demand: Family planning services provided by the Mexican Ministry of Health. International Family Planning Perspectives 25(3): 119–124, 138. Sep. 1999.
77. HUBER, D. A case study: DMPA reintroduced in the Philippines. Presented at the USAID Cooperating Agencies Meeting, Feb. 23, 1994 (abstract).
78. HUBER, D. (Management Sciences for Health) [Injectables in Afghanistan and the Philippines] Personal communication, Dec. 1, 2005 and Aug. 2, 2006.
79. HUBER, L.R., HOGUE, C.J., STEIN, A.D., DREWS, C., ZIEMAN, M., KING, J., and SCHAYES, S. Contraceptive use and discontinuation: Findings from the contraceptive history, initiation, and choice study. American Journal of Obstetrics and Gynecology 194(5): 1290–1295. May 2006.
*†80. HUTIN, Y., HAURI, A., CHIARELLO, L., CATLIN, M., STILWELL, B., GHEBREHIWET, T., and GARNER, J. Best infection control practices for intradermal, subcutaneous, and intramuscular needle injections. Bulletin of the World Health Organization 81(7): 491–500. 2003. (Available: http://www.who.int/bulletin/volumes/81/7/en/Hutin0703.pdf)
*81. HUTIN, Y.J., HAURI, A.M., and ARMSTRONG, G.L. Use of injections in healthcare settings worldwide, 2000: Literature review and regional estimates. British Medical Journal 327(7423): 1075. Nov. 8, 2003.
82. INFO PROJECT and JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH/CENTER FOR COMMUNICATION PROGRAMS. Choosing injectables: Your family health. [Radio Spot]. Winter 2003.
*†83. INTERNATIONAL PLANNED PARENTHOOD FEDERATION (IPPF). Directory of hormonal contraceptives. (http://contraceptive.ippf.org/(0zkcmu55dkyfhq45kbxfvpnw)/Default.aspx) IPPF, Jan. 26, 2006.
84. INTERNATIONAL PLANNED PARENTHOOD FEDERATION (IPPF) INTERNATIONAL MEDICAL ADVISORY PANEL (IMAP). Statement on hormonal methods of contraception. London, IPPF, May 2002. 19 p. (Available: http://content.ippf.org/output/ORG/files/6529.pdf)
85. INTERNATIONAL SCIENCE AND TECHNOLOGY INSTITUTE INC. Health, population and nutrition projects. {http://www.istiinc.com/Overview/Health_Nutri_Pj.htm} International Science and Technology Institute Inc., 2006.
86. JACOBS, L. First, do no harm. Gavi Alliance, Mar. 2001. (Immunization Focus Special Feature) (Available: http://www.gavialliance.org/Resources_Documents/Immunization_Focus/Download/feature_3.php)
†87. JAIN, J., JAKIMIUK, A.J., BODE, F.R., ROSS, D., and KAUNITZ, A.M. Contraceptive efficacy and safety of DMPA-SC. Contraception 70(4): 269–275. Oct. 2004.
*88. JANOWITZ, B. Make better use of provider time in reproductive health clinics, FRONTIERS Program Brief No. 7. Washington D.C., Population Council, Aug. 2006. (Available: http://www.popcouncil.org/pdfs/frontiers/pbriefs/Time_Use_PB_final.pdf)
89. JANOWITZ, B., CHEGE, J., THOMPSON, A., RUTENBERG, N., and HOMAN, R. Community-based distribution in Tanzania: Costs and impacts of alternative strategies to improve worker performance. International Family Planning Perspectives 26(4): 158–160, 193–155. Dec. 2000.
*90. JANOWITZ, B., MEASHAM, D., and WEST, C. Cost of services. In: Financing of Family Planning Services in Sub-Saharan Africa. Research Triangle Park, North Carolina, Family Health International, 1999. (Available: http://www.fhi.org/en/RH/Pubs/booksReports/fpfinancing/servcost.htm)
91. JANSSENS, A. (United Nations Population Fund) [Emergency shipments of injectables] Personal communication, Jun. 1, 2006.
92. JHPIEGO. Community-based provision of injectables: Current developments and collaboration for action meeting. Baltimore, Jan. 9, 2006.
*93. JOHN SNOW, INC. and WORLD HEALTH ORGANIZATION (WHO). Do no harm: Injection safety in the context of infection prevention and control, training tools and job aids. 2006. (Forthcoming)
*94. JOHN SNOW, INC./DELIVER. The logistics handbook: A practical guide for supply chain managers in family planning and health programs. Arlington, Virginia, John Snow, Inc./DELIVER, for the U.S. Agency for International Development, 2000.
95. KEENER, T. USAID: Bundling for family planning injections. Proceedings of the Safe Injection Global Network (SIGN) Annual Meeting, New Delhi, Aug. 30–31, 2001. (Available: http://www.who.int/injection_safety/sign/meetings/past/en/2001MeetingReport.pdf)
96. KIM, Y.M., PUTJUK, F., BASUKI, E., and KOLS, A. Increasing patient participation in reproductive health consultations: An evaluation of "Smart Patient" coaching in Indonesia. Patient Education and Counseling 50(2): 113–122. Jun. 2003.
97. KINZETT, S. (Program for Appropriate Technology in Health) [Forecasting for injectables in Kenya] Personal communication, Sep. 22, 2006.
98. KRISTENSEN, D.D. (Program for Appropriate Technology in Health) [Delivery systems and shelf life of injectables] Personal communication, Jun. 28, 1995.
*†99. LANDE, R.E. New era for injectables. Population Reports, Series K, No. 5. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Aug. 1995. 31 p.
*†100. LEI, Z.W., WU, S.C., GARCEAU, R.J., JIANG, S., YANG, Q.Z., WANG, W.L., and VANDER MEULEN, T.C. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception 53(6): 357–361. Jun. 1996.
101. LEON, F.R., MONGE, R., ZUMARAN, A., GARCIA, I., and RIOS, A. Length of counseling sessions and the amount of relevant information exchanged: A study in Peruvian clinics. International Family Planning Perspectives 27(1): 28–33, 46. Mar. 2001.
102. LIGGERI, E. (Pfizer) [DMPA-SC] Personal communication, Feb. 2006.
103. LIGGERI, E. An update on Pfizer's strategy to increase access to injectable contraceptives. Presented at the Community-Based Provision of Injectables: Current Developments and Collaboration for Action Meeting, Baltimore, Jan. 9, 2006.
104. LOGEZ, S. (World Health Organization) [Placing orders for injectables] Personal communication, Aug. 9, 2006.
105. LU, E.R. (JHPIEGO) [Injectables: Training and provision] Personal communication, May 5, 2006.
106. LUMBIGANON, P., RUGPAO, S., PHANDHU-FUNG, S., LAOPAIBOON, M., VUDHIKAMRAKSA, N., and WERAWATAKUL, Y. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: A multicentre case-control study. British Journal of Obstetrics and Gynaecology 103(9): 909–914. Sep. 1996.
*107. MATHENY, G. Family planning programs: Getting the most for the money. International Family Planning Perspectives 30(3): 134–138. Sep. 2004.
*108. MAULDIN, W.P. and MILLER, V.C. Contraceptive use and commodity costs in developing countries, 1994–2005. New York, United Nations Population Fund (UNFPA), 1994. 64 p.
*109. MCCARRAHER, D. Factors to consider in adding injectables to CBD programs. Presented at the Community-Based Provision of Injectables: Current Developments and Collaboration for Action Meeting, Baltimore, Jan. 9, 2006.
110. MCINTOSH, N. Nepal reproductive health training sector assessment and five-year action plan (1993–1998) Aug. 1993. (JHPIEGO Technical Report No. FCA-02)
111. MEDICAL BOARD OF CALIFORNIA CONSUMER INFORMATION UNIT. Medical assistant laws and regulations. Sacramento, California, Mar. 25, 2002. (Available: http://www.rn.ca.gov/practice/pdf/npr-b-41medbrdsec.pdf)
112. MENDOZA, I. and VERNON, R. Promoting reproductive health services in rural communities in Honduras. Population Council, Frontiers in Reproductive Health, Jun. 15, 2001. 11 p. (Available: http://www.popcouncil.org/pdfs/frontiers/FR_FinalReports/Honduras_Nurse_roles.pdf)
*113. MERCER, A., ASHRAF, A., HUQ, N.L., HASEEN, F., UDDIN, A.H., and REZA, M. Use of family planning services in the transition to a static clinic system in Bangladesh: 1998–2002. International Family Planning Perspectives 31(3): 115–123. Sep. 2005.
114. MILDVAN, D., YARRISH, R., MARSHAK, A., HUTMAN, H.W., MCDONOUGH, M., LAMSON, M., and ROBINSON, P. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. Journal of Acquired Immune Deficiency Syndromes 29(5): 471–477. Apr. 15, 2002.
115. MILLER, M.A. and PISANI, E. The cost of unsafe injections. Bulletin of the World Health Organization 77(10): 808-811. 1999. (Available: http://whqlibdoc.who.int/bulletin/1999/Vol77-No10/bulletin_1999_77(10)_808-811.pdf)
116. MOHR, D.C., BOUDEWYN, A.C., LIKOSKY, W., LEVINE, E., and GOODKIN, D.E. Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine 23(2): 125–132. Spring 2001.
117. MOLLEMA, E.D., SNOEK, F.J., HEINE, R.J., and VAN DER PLOEG, H.M. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: Opportunities for screening. Diabetic Medicine 18(8): 671–674. Aug. 2001.
118. MOLYNEAUX, J. The evolution of contraceptive pricing in Indonesia: A final report to the POLICY Project. Washington, D.C., Futures Group International, The POLICY Project, Aug. 2000. 29 p. (Available: http://www.policyproject.com/pubs/commissionedresearch/rand2-final.pdf)
119. MONEY, D.M. Antiviral and antiretroviral use in pregnancy. Obstetrics and Gynecology Clinics of North America 30(4): 731–749, vii. Dec. 2003.
120. MOORE, L.L., VALUCK, R., MCDOUGALL, C., and FINK, W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 52(4): 215–219. Oct. 1995.
*121. MORRONI, C., MYER, L., MOSS, M., and HOFFMAN, M. Preferences between injectable contraceptive methods among South African women. Contraception 73(6): 598–601. Jun. 2006.
122. MOSHER, W.D., MARTINEZ, G.M., CHANDRA, A.C., AMBA, J.C., and WILSON, S.J. Use of contraception and use of family planning services in the United States: 1982–2002. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Dec. 10, 2004. (Advance Data from Vital and Health Statistics No. 350) (Available: http://www.cdc.gov/NCHS/data/ad/ad350.pdf)
123. MWEBESA, W. Operations research & PVO programs: Lessons from Save the Children. Proceedings of the Community-Based Family Planning: Strategies and Approaches, Washington D.C., May 16, 2006.
124. NAMUN, K. and MUNGUAS, M. Community based distributor (CBD) nurse gives a depo injection to a mother in Ainsi village, Markham District, Morobe Province, Papua New Guinea. [Photo] 2005.
*125. NECOCHEA, E. and BOSSEMEYER, D. Standards-based management and recognition—A field guide: A practical approach for improving the performance and quality of health services. Baltimore, JHPIEGO, 2005. 84 p. (Available: http://pdf.usaid.gov/pdf_docs/PNADF143.pdf)
126. NELSON, A.L. Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception. Journal of Reproductive Medicine 41(5 Suppl): 391–400. May 1996.
127. NERSESIAN, P. (John Snow, Inc.) [Logistics for injectable contraceptives] Personal communication, Aug. 21, 2006.
*128. NERSESIAN, P., CESARZ, V., COCHRAN, A., MBOYANE, J., and SCHMIDT, K. Safe injection and waste management: A reference for logistics advisors. Arlington, Virginia, John Snow, Inc./DELIVER for the U.S. Agency for International Development, 2004.
129. NSUBUGA, F.M. and JAAKKOLA, M.S. Needle stick injuries among nurses in sub-Saharan Africa. Tropical Medicine & International Health 10(8): 773–781. Aug. 2005.
†130. PARDTHAISONG, T. Return of fertility after use of the injectable contraceptive Depo Provera: Up-dated data analysis. Journal of Biosocial Science 16(1): 23–34. Jan. 1984.
131. PARDTHAISONG, T., GRAY, R.H., MCDANIEL, E.B., and CHANDACHAM, A. Steroid contraceptive use and pregnancy outcome. Teratology 38(1): 51–58. Jul. 1988.
132. PARIANI, S., HEER, D.M., and VAN ARSDOL, M.D.J. Does choice make a difference to contraceptive use? Evidence from East Java. Studies in Family Planning 22(6): 384–390. Nov.–Dec. 1991.
133. PATHFINDER INTERNATIONAL. Improving the efficiency of clinics in Bangladesh. Jul. 2006. (NSDP Brief No. 6)
134. PATHFINDER INTERNATIONAL and JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH/CENTER FOR COMMUNICATION PROGRAMS. Depo-Provera TV spots: Sisters: Three women in the clinic. 2001.
†135. PAUL, C., SKEGG, D.C., and WILLIAMS, S. Depot medroxyprogesterone acetate: Patterns of use and reasons for discontinuation. Contraception 56(4): 209–214. Oct. 1997.
136. PEARCE, B. "Injection safety," South Africa: Behaviour change and communication. Making Medical Injections Safer/John Snow, Inc., Mar. 2004. (Available: http://www.baselpretoria.org.za/Documents/IS%20HCW/BronwynPearce.pdf)
137. PERNOLL, M.L. Benson & Pernoll's handbook of obstetrics and gynecology. New York, McGraw-Hill, 2001. 908 p.
138. PHILLIPS, J.F., BAWAH, A.A., and BINKA, F.N. Accelerating reproductive and child health program development: The Navrongo Initiative in Ghana. New York Population Council, 2005. 27 p. (Available: http://www.popcouncil.org/pdfs/wp/208.pdf)
*139. PHILLIPS, J.F., HOSSAIN, M.B., HUQUE, A.A., and AKBAR, J. A case study of contraceptive introduction: Domiciliary depot-medroxy progesterone acetate services in rural Bangladesh. In: Segal, S.J., Tsui, A.O., and Rogers, S.M., eds. Demographic and Programmatic Consequences of Contraceptive Innovations. New York, Plenum Press, 1989. p. 227–248.
*140. PIOTROW, P.T., KINCAID, D.L., RIMON, J.G.D., RINEHART, W., and SAMSON, K. Health communication: Lessons from family planning and reproductive health. Westport, Connecticut, Praeger, 1997. 307 p.
141. PISCITELLI, S.C. and GALLICANO, K.D. Interactions among drugs for HIV and opportunistic infections. New England Journal of Medicine 344(13): 984–996. Mar. 29, 2001.
*142. POPULATION ACTION INTERNATIONAL. Defining reproductive health supplies: A survey of international programs. Washington, D.C., Population Action International, Apr. 2001. 8 p.
143. POPULATION COUNCIL. Focus on the Philippine DMPA reintroduction program: Continuing users vs. drop-outs. Manila, Population Council, Apr. 1996. (Research News No. 7) 2 p.
144. POPULATION COUNCIL FRONTIERS IN REPRODUCTIVE HEALTH, DKT INDIA, ENGENDERHEALTH, and CENTRE FOR OPERATIONS RESEARCH AND TRAINING (CORT). Introducing DMPA injectable contraceptives to private medical practitioners in urban Gujarat. New Delhi, Population Council Frontiers in Reproductive Health, DKT International, EngenderHealth, CORT, Mar. 2003. 43 p.
145. POPULATION SERVICES INTERNATIONAL (PSI). Products and services: Injectable contraception. (http://www.psi.org/our_programs/products/injectables.html) PSI, Sep. 27, 2006.
146. POPULATION SERVICES INTERNATIONAL, JOHNS HOPKINS UNIVERSITY POPULATION COMMUNICATION SERVICES, SANTÉ FAMILIALE ET PRÉVENTION DU SIDA (SFPS), and AGENCE IVOIRIENNE DE MARKETING SOCIAL. [Gold circle: Auntie Fatou's advice: More version]. [Video]. SFPS, Gold Circle, 2002.
147. PRATA, N., VAHIDNIA, F., POTTS, M., and DRIES-DAFFNER, I. Revisiting community-based distribution programs: Are they still needed? Contraception 72(6): 402–407. Dec. 2005.
148. PREBLE, E.A., HUBER, D., and PIWOZ, E.G. Family planning and the prevention of mother-to-child transmission of HIV: Technical and programmatic issues. Arlington, Virginia, Advance Africa, Feb. 21, 2003. 38 p. (Available: http://www.advanceafrica.org/publications_and_presentations/Technical_Papers/TP_FP_and_PMTCT.pdf)
149. PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH). Giving safe injections: Using auto-disable syringes for immunization. Seattle, Washington, PATH, Sep. 2001. (Available: http://www.path.org/files/SI_Giving_Safe_Injections_complete.pdf)
150. PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH). SoloShot. PATH, May 2005. (Technology Solutions for Global Health) 1 p. (Available: http://www.path.org/files/TS_update_soloshot.pdf)
*151. PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH). Introducing auto-disable syringes and sharps disposal containers with DMPA. PATH, Jul. 19, 2006. 10 p. (Available: http://www.path.org/files/SI_CNVP15904_English.pdf)
152. PSP-ONE PROJECT. Our work in India: Access to high-quality affordable injectable contraceptives through the DIMPA network. {http://www.psp-one.com/section/technicalareas/country_work/india} 2006.
153. RAHIMY, M.H. and RYAN, K.K. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): Assessment of return of ovulation after three monthly injections in surgically sterile women. Contraception 60(4): 189–200. Oct. 1999.
*154. RAHMAN, M.B., JANOWITZ, B., CHOWDHURY, J.H., and JAMIL, K. Productivity and costs for family planning service delivery in Bangladesh: The government program. Associates for Community and Population Research, Jun. 1996. 46 p.
155. RAMAN-WILMS, L., TSENG, A.L., WIGHARDT, S., EINARSON, T.R., and KOREN, G. Fetal genital effects of first-trimester sex hormone exposure: A meta-analysis. Obstetrics and Gynecology 85(1): 141–149. Jan. 1995.
*156. RAO, R. and PANDIT, T. Nepal: Contraceptive security. Issues, findings, and recommendations. Arlington, Virginia, John Snow, Inc./DELIVER, for the U.S. Agency for International Development, Jan. 2004. 30 p. (Available: http://portalprd1.jsi.com/pls/portal/docs/PAGE/DEL_CONTENT_PGG/DEL_PUBLICATION_PG1/DEL_COUNTRY_RPT_PG1/NEPAL_CONTRACEPTIVE-SECURITY_R2.PDF)
157. RAWLINS, B., GARRISON, K., LYNAM, P., BRECHIN, S.J., and NJERU, A. High-performing reproductive healthcare facilities in Kenya: Why they exceed expectations. Baltimore JHPIEGO, Mar. 2003. 28 p.
158. REPRODUCTIVE HEALTH ADVISORY BOARD, MINISTRY OF HEALTH, and REPUBLIC OF KENYA. Contraceptive commodities procurement plan, 2003–2006. Ministry of Health, Feb. 2003. 32 p.
159. RHINTERCHANGE. Summary of shipment reports. {http://rhi.rhsupplies.org/rhi/index.do} Supply Initiative, 2006.
160. ROBERTS, C. Universal precautions: Improving the knowledge of trained nurses. British Journal of Nursing 9(1): 43-47. Jan. 13–26, 2000.
161. ROBEY, B. and STAUFFER, P. Helping the news media cover family planning. Population Reports, Series J, No. 42. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Nov. 1995. 1–27 p. (Available: http://www.infoforhealth.org/pr/j42edsum.shtml)
*162. ROGERS, E.M. Diffusion of innovations. 4th ed. Free Press, 1995. 519 p.
*163. ROSS, J., STOVER, J., and ADELAJA, D. Profiles for family planning and reproductive health programs: 116 countries. Futures Group, 2005. 182 p. (Available: http://www.constellafutures.com/Documents/Profiles116FP2ed.pdf)
*164. ROUTH, S., ASHRAF, A., STOECKEL, J., and BARKAT-E-KHUDA. Consequence of the shift from domiciliary distribution to site-based family planning services in Bangladesh. Studies in Family Planning 27(2): 82–89. Jun. 2001.
*165. RUMINJO, J.K., SEKADDE-KIGONDU, C.B., KARANJA, J.G., RIVERA, R., and NASUTION, M. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya. Contraception 72: 138–145. 2005.
166. SALEM, H.T., SALAH, M., ALY, M.Y., THABET, A.I., SHAABAN, M.M., and FATHALLA, M.F. Acceptability of injectable contraceptives in Assiut, Egypt. Contraception 38(6): 697–710. Dec. 1988.
167. SANG, G.W., SHAO, Q.X., GE, R.S., GE, J.L., CHEN, J.K., SONG, S., FANG, K.J., HE, M.L., LUO, S.Y., CHEN, S.F., and ET AL. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. I. Contraceptive efficacy and side effects. Contraception 51(3): 167–183. Mar. 1995.
168. SANGI-HAGHPEYKAR, H., POINDEXTER, A.N.D., BATEMAN, L., and DITMORE, J.R. Experiences of injectable contraceptive users in an urban setting. Obstetrics and Gynecology 88(2): 227–233. Aug. 1996.
169. SAROJINI, N.B. and MURTHY, L. Why women's groups oppose injectable contraceptives. Indian Journal of Medical Ethics 13(1). Jan.-Mar. 2005.
170. SCHLAFF, W.D., CARSON, S.A., LUCIANO, A., ROSS, D., and BERGQVIST, A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility and Sterility 85(2): 314–325. Feb. 2006.
171. SCHWALLIE, P.C. and ASSENZO, J.R. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: A review. Contraception 10(2): 181–202. Aug. 1974.
*172. SETTY, V. Organizing work better. Population Reports, Series Q, No. 2. Baltimore, Johns Hopkins Bloomberg School of Public Health, The INFO Project, Winter 2004. (Available: http://www.infoforhealth.org/pr/q02/index.shtml)
*173. SHELTON, J.D. Contraception for women on first-line antiretrovirals (ARVs). Baltimore, The INFO Project at the Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs, Mar. 25, 2005. (Global Health Technical Briefs) (Available: http://www.maqweb.org/techbriefs/tb5arv.shtml)
174. SILBERSTEIN, S.D. Hormone-related headache. Medical Clinics of North America 85(4): 1017–1035. Jul. 2001.
*175. SIMMONS, R., FAJANS, P., and LUBIS, F. Contraceptive introduction and the management of choice: The role of Cyclofem in Indonesia. Contraception 49(5): 509–525. May 1994.
176. SMIT, J. (University of Witwatersrand) [Injectables use in South Africa] Personal communication, August 18, 2006.
*177. SMIT, J., GRAY, A., MCFADYEN, L., and ZUMA, K. Counting the costs: Comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa. BMC Health Services Research 1(1): 4. 2001.
178. SMITH, J.S., GREEN, J., BERRINGTON DE GONZALEZ, A., APPLEBY, P., PETO, J., PLUMMER, M., FRANCESCHI, S., and BERAL, V. Cervical cancer and use of hormonal contraceptives: A systematic review. Lancet 361(9364): 1159–1167. Apr. 5, 2003.
179. SOLHEIM, F. An assessment of quality of life in women treated with Depo-Provera in Sweden. In: Zambrano, D., ed. Depo-Provera (medroxyprogesterone acetate) for contraception: A current perspective of scientific, clinical and social issues Oxford, England, Oxford Clinical Communications, 1993. p. 61–72.
*180. SOLO, J., JACOBSTEIN, R., and MALEMA, D. Malawi case study: Choice, not chance. A repositioning family planning case study. New York City, EngenderHealth, ACQUIRE Project, Sep. 2005. (ACQUIRE Report) 40 p. (Available: http://www.acquireproject.org/fileadmin/user_upload/ACQUIRE/Malawi_case_study.pdf)
*181. SOLTER, C. Module 6: DMPA injectable contraceptive. In: Comprehensive reproductive health and family planning program training curriculum. Watertown, Massachusetts, Pathfinder International, Sep. 1999. (Available: http://www.pathfind.org/pf/pubs/module_6.pdf)
182. STANBACK, J. (Family Health International) [Community-based distribution of injectables in Uganda] Personal communication, May 2, 2006.
*183. STANBACK, J., MBONYE, A., LEMELLE, J., BEKIITA, M., SSEKITO, G., and KAJURA, N.J. Safety and feasibility of community-based distribution of Depo-Provera in Nakasongola, Uganda. Final Report. Research Triangle Park, North Carolina, Family Health International, Uganda Ministry of Health, Save the Children, Nakasongola Local Government, Jun. 2005. 20 p.
184. STANWOOD, N.L., EASTWOOD, K., and CARLETTA, A. Self-injection of monthly combined hormonal contraceptive. Contraception 73(1): 53–55. Jan. 2006.
185. SULLIVAN, R.S. The competency-based approach to training. JHPIEGO Corporation, Sep. 1995. (JHPIEGO Strategy Paper No. 1) (Available: http://www.reproline.jhu.edu/english/6read/6training/cbt/sp601web.pdf)
*186. SULLIVAN, T.M., BERTRAND, J.T., RICE, J., and SHELTON, J.D. Skewed contraceptive method mix: Why it happens, why it matters. Journal of Biosocial Science 38(4): 501–521. 2006.
187. TALAAT, M., EL-OUN, S., KANDEEL, A., ABU-RABEI, W., BODENSCHATZ, C., LOHINIVA, A.L., HALLAJ, Z., and MAHONEY, F.J. Overview of injection practices in two governorates in Egypt. Tropical Medicine & International Health 8(3): 234–241. Mar. 2003.
188. TANEEPANICHSKUL, S., REINPRAYOON, D., and JAISAMRARN, U. Effects of DMPA on weight and blood pressure in long-term acceptors. Contraception 59(5): 301–303. May 1999.
189. TAVROW, P., KIM, Y.M., and MALIANGA, L. Measuring the quality of supervisor-provider interactions in health care facilities in Zimbabwe. International Journal for Quality in Health Care 14 Suppl.: 57–66. 2002.
*†190. TRUSSELL, J. Contraceptive efficacy. In: Contraceptive Technology. 18th ed. New York, Ardent Media, 2004. p. 773–845.
191. U.S. CENSUS BUREAU. International Database (IDB). {http://www.census.gov/ipc/www/idbprint.html} U.S. Census Bureau, Population Division/International Programs Center, 2006.
*192. U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION. Universal precautions for prevention of transmission of HIV and other bloodborne infections. 1996. (Available: http://www.cdc.gov/ncidod/dhqp/bp_universal_precautions.html)
193. U.S. FOOD AND DRUG ADMINISTRATION (USFDA). Black box warning added concerning long-term use of Depo-Provera contraceptive injection. Nov. 17, 2004. (FDA Talk Paper) (Available: http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html)
*194. UNITED NATIONS (UN). World contraceptive use 2005. [Wall Chart]. New York, UN, Jan. 2006.
195. UNITED NATIONS CHILDREN'S FUND (UNICEF). 2005 AD syringes projections: Quantities and pricing. UNICEF, Jan. 2005. 1 p. (Available: http://www.unicef.org/supply/files/Projections_AD_Syringes_2005.pdf)
196. UNITED NATIONS POPULATION FUND (UNFPA). Reproductive health essentials: Securing the supply. New York, UNFPA, 2002. 34 p. (Available: http://www.unfpa.org/upload/lib_pub_file/39_filename_securingsupply_eng.pdf)
*197. UNITED NATIONS POPULATION FUND (UNFPA). Alliances, special projects and emergency procurement: Global contraceptive commodity programme (GCCP). {http://www.unfpa.org/procurement/alliances.htm} UNFPA, 2006.
†198. UPADHYAY, U.D. Informed choice in family planning: Helping people decide. Population Reports Series J, No. 50. Baltimore, Johns Hopkins Bloomberg School of Public Health, Population Information Program, Spring 2001. 39 p. (Available: http://www.infoforhealth.org/pr/j50edsum.shtml)
199. VERCELLINI, P., DE GIORGI, O., OLDANI, S., CORTESI, I., PANAZZA, S., and CROSIGNANI, P.G. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. American Journal of Obstetrics and Gynecology 175(2): 396–401. Aug. 1996.
200. VILLANUEVA, Y., MENDOZA, I., RODRIGUZ, S., and VERNON, R. Expansion of the role of nurse auxiliaries in the delivery of reproductive health services in Honduras. Population Council, Jun. 15, 2001. (Available: http://pdf.dec.org/pdf_docs/PNACM375.pdf)
201. WORLD BANK GROUP. Health, nutrition, and population statistics: 2005 Demographic projections. World Bank Group, 2006.
*†202. WORLD HEALTH ORGANIZATION (WHO). Multinational comparative clinical trial of long-acting injectable contraceptives: Norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report. Contraception 28(1): 1–20. Jul. 1983.
*203. WORLD HEALTH ORGANIZATION (WHO). A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given in three-monthly at doses of 100mg or 150mg: I. Contraceptive efficacy and side effects. Contraception 34(3): 223–235. Sep. 1986.
204. WORLD HEALTH ORGANIZATION (WHO). Injectable contraceptives: Their role in family planning care. Geneva, WHO, 1990. 117 p.
205. WORLD HEALTH ORGANIZATION (WHO). Facts about once-a-month injectable contraceptives: Memorandum from a WHO meeting. Bulletin of the World Health Organization 71(6): 677–689. 1993. (Available: http://whqlibdoc.who.int/bulletin/1993/Vol71-No6/bulletin_1993_71(6)_677-689.pdf)
206. WORLD HEALTH ORGANIZATION (WHO). Equipment performance specifications and test procedures. Global Programme for Vaccines and Immunization, 1997. 19 p. (Available: http://www.who.int/vaccines-documents/DocsPDF/www9512/e10-9512.pdf)
*207. WORLD HEALTH ORGANIZATION (WHO). Safe management of wastes from health-care activities. Geneva, WHO, 1999. 242 p. (Available: http://www.who.int/injection_safety/toolbox/docs/en/waste_management.pdf)
208. WORLD HEALTH ORGANIZATION (WHO). Aide-memoire for a national strategy for the safe and appropriate use of injections. Geneva, WHO, 2000. 2 p. (Available: http://www.who.int/injection_safety/about/country/en/AMENG.pdf)
*209. WORLD HEALTH ORGANIZATION (WHO). Best infection control practices for skin-piercing intradermal, subcutaneous, and intramuscular injections. Geneva, WHO, Nov. 2001. 2 p. (Available: http://www.who.int/injection_safety/toolbox/en/LeafletBestPracticesPrinter.pdf)
*210. WORLD HEALTH ORGANIZATION (WHO). Guiding principles to ensure injection device security. Geneva, WHO, 2003. (Available: http://www.who.int/injection_safety/WHOGuidPrinciplesInjEquipFinal.pdf)
211. WORLD HEALTH ORGANIZATION (WHO). Aide-memoire: For infection prevention and control in a health care facility. Geneva, WHO, Aug. 2004. 2 p. (Available: http://www.who.int/medical_devices/publications/en/AM_InfectionControl.pdf)
*†212. WORLD HEALTH ORGANIZATION (WHO). Medical eligibility criteria for contraceptive use. 3rd ed. Geneva, WHO, Department of Reproductive Health and Research, 2004. 168 p. (Available: http://www.who.int/reproductive-health/publications/mec/index.htm)
213. WORLD HEALTH ORGANIZATION (WHO). Policy paper: Safe health care and waste management. Geneva, WHO, Aug. 2004. 2 p. (Available: http://www.who.int/water_sanitation_health/medicalwaste/en/hcwmpolicye.pdf)
214. WORLD HEALTH ORGANIZATION (WHO). Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach. Geneva, WHO, 2004. 68 p. (Available: http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf)
*†215. WORLD HEALTH ORGANIZATION (WHO). Selected practice recommendations for contraceptive use. 2nd ed. Geneva, WHO, Department of Reproductive Health and Research, 2004. 170 p. (Available: http://www.who.int/reproductive-health/publications/spr/spr.pdf)
*†216. WORLD HEALTH ORGANIZATION (WHO). WHO statement on hormonal contraception and bone health. Weekly Epidemiological Record 80(35): 302–304. Sep. 2005.
*217. WORLD HEALTH ORGANIZATION (WHO). Management of waste from injection activities at district level: Guidelines for district health managers. Geneva, WHO, 2006. (Available: http://www.who.int/water_sanitation_health/medicalwaste/mwinjections.pdf)
218. WORLD HEALTH ORGANIZATION (WHO). Universal precautions, including injection safety. {http://www.who.int/hiv/topics/precautions/universal/en/} WHO, 2006.
*219. WORLD HEALTH ORGANIZATION (WHO) and JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH (JHSPH) CENTER FOR COMMUNICATION PROGRAMS. Family planning: A global handbook for providers. JHSPH, The INFO Project, and WHO (forthcoming).
†220. WORLD HEALTH ORGANIZATION (WHO), SPECIAL PROGRAMME OF RESEARCH DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION, and TASK FORCE ON LONG-ACTING SYSTEMIC AGENTS FOR FERTILITY REGULATION. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone oenanthate and medroxyprogesterone acetate: Bleeding patterns and side effects. Contraception 17(5): 395–406. May 1978.
221. WORLD HEALTH ORGANIZATION (WHO), SPECIAL PROGRAMME OF RESEARCH DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION, and TASK FORCE ON LONG-ACTING SYSTEMIC AGENTS FOR FERTILITY REGULATION. A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection: Contraceptive efficacy and side effects. Contraception 37(1): 1–20. Jan. 1988.
222. WORLD HEALTH ORGANIZATION (WHO) and SPECIAL PROGRAMME OF RESEARCH DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION TASK FORCE FOR EPIDEMIOLOGICAL RESEARCH ON REPRODUCTIVE HEALTH. Effects of contraceptives on hemoglobin and ferritin. Contraception 58(5): 261–273. Nov. 1998.
*223. WORLD HEALTH ORGANIZATION (WHO), UNITED NATIONS CHILDREN'S FUND (UNICEF), and UNITED NATIONS POPULATION FUND (UNFPA). Safety of injections: WHO-UNICEF-UNFPA joint statement on the use of auto-disable syringes in immunization services. 2003. 4 p. (Available: http://www.who.int/vaccines-documents/DocsPDF99/www9948.pdf)
Addenda
224. FAJANS, P., NGUYEN THI THOM, WHITTAKER, M., SATIA, J., TRAN THI PHUONG MAI, TRINH DINH CAN, DO THI THANH NHAN, and NEWTON, N. Strategic choices in scaling-up: Introducing injectable contraception and improving quality of care in Vietnam. In: Simmons, R., Fajans, P., and Ghiron, L., eds. Scaling Up Health Service Delivery: From Pilot Innovations to Policies and Programmes. Geneva, World Health Organization, 2006. (Draft) (Available: http://www.expandnet.net/PDFs/Fajans_etal.pdf)
225. KILLIAN, R. (EngenderHealth) [Quality of care in the Community-Based Health Planning and Services (CHPS) Initiative in Ghana] Personal communication, Oct. 9, 2006.
226. SKIBIAK, J.P., MIJERE, P., and ZAMA, M. Expanding contraceptive choice and improving quality of care in Zambia's Copperbelt: A case study in moving from pilot projects to regional programmes. In: Simmons, R., Fajans, P., and Ghiron, L., eds., Scaling Up Health Service Delivery: From Pilot Innovations to Policies and Programmes. Geneva, World Health Organization, 2006. (Draft) (Available: http://www.expandnet.net/PDFs/Skibiak_etal.pdf)
227. THORN, N.T., HIEU, D.T., NHAN, V.Q., NHAN, D.T., WHITTAKER, M., FAJANS, P., and SATIA, J. The strategic approach to the introduction of DMPA as an opportunity to improve quality of care for all contraceptive methods in Vietnam. Asia-Pacific Population Journal 15(4): 63–88. Dec. 2000. (Available: http://www.unescap.org/ESID/psis/population/journal/2000/v15n4a4.pdf)
|
Order this report
Download PDF
E-mail this page 
See Companion INFO Reports on "Injectable Contraceptives: Tools for Providers"
